Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's effic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2017-08-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/3/3/00004-2017.full |